Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free ARCT Stock Alerts

Arcturus Therapeutics (ARCT) Competitors

Arcturus Therapeutics logo
$13.74 +0.87 (+6.76%)
Closing price 04:00 PM Eastern
Extended Trading
$13.52 -0.22 (-1.56%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ARCT vs. MAZE, COAG, ANAB, AAPG, and INBX

Should you buy Arcturus Therapeutics stock or one of its competitors? Arcturus Therapeutics's main competitors and comparable companies include Maze Therapeutics (MAZE), Hemab Therapeutics (COAG), AnaptysBio (ANAB), Ascentage Pharma Group International (AAPG), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arcturus Therapeutics compare to Maze Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Arcturus Therapeutics has higher earnings, but lower revenue than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$82.03M4.76-$65.78M-$3.31N/A
Maze Therapeutics$167.50M8.99-$131.12M-$2.52N/A

Arcturus Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 60.12%. Maze Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 133.86%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67
Maze Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.08

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Arcturus Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market.

Maze Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Maze Therapeutics' return on equity of -34.94% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-317.62% -46.54% -36.46%
Maze Therapeutics N/A -34.94%-30.18%

In the previous week, Maze Therapeutics had 14 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 24 mentions for Maze Therapeutics and 10 mentions for Arcturus Therapeutics. Maze Therapeutics' average media sentiment score of 0.69 beat Arcturus Therapeutics' score of 0.15 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Maze Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Maze Therapeutics beats Arcturus Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Arcturus Therapeutics had 7 more articles in the media than Hemab Therapeutics. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Arcturus Therapeutics' score of 0.15 indicating that Hemab Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hemab Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hemab Therapeutics presently has a consensus target price of $51.40, suggesting a potential upside of 62.56%. Arcturus Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 60.12%. Given Hemab Therapeutics' higher possible upside, analysts clearly believe Hemab Therapeutics is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67

94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hemab Therapeutics has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/A-$24.78N/A
Arcturus Therapeutics$82.03M4.76-$65.78M-$3.31N/A

Hemab Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Hemab Therapeutics' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Arcturus Therapeutics -317.62%-46.54%-36.46%

Summary

Arcturus Therapeutics beats Hemab Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Arcturus Therapeutics compare to AnaptysBio?

Arcturus Therapeutics (NASDAQ:ARCT) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

AnaptysBio has a net margin of 82.37% compared to Arcturus Therapeutics' net margin of -317.62%. AnaptysBio's return on equity of 112.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-317.62% -46.54% -36.46%
AnaptysBio 82.37%112.00%2.20%

94.5% of Arcturus Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 31.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arcturus Therapeutics had 3 more articles in the media than AnaptysBio. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 7 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.23 beat Arcturus Therapeutics' score of 0.15 indicating that AnaptysBio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
AnaptysBio
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

AnaptysBio has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$82.03M4.76-$65.78M-$3.31N/A
AnaptysBio$234.60M5.86-$13.23M$5.378.56

Arcturus Therapeutics currently has a consensus price target of $22.00, indicating a potential upside of 60.12%. AnaptysBio has a consensus price target of $77.79, indicating a potential upside of 69.28%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts clearly believe AnaptysBio is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67
AnaptysBio
1 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.71

Arcturus Therapeutics has a beta of 2.48, meaning that its share price is 148% more volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

AnaptysBio beats Arcturus Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Ascentage Pharma Group International?

Arcturus Therapeutics (NASDAQ:ARCT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Arcturus Therapeutics had 4 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 6 mentions for Ascentage Pharma Group International. Arcturus Therapeutics' average media sentiment score of 0.15 beat Ascentage Pharma Group International's score of 0.11 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

94.5% of Arcturus Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arcturus Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$82.03M4.76-$65.78M-$3.31N/A
Ascentage Pharma Group International$82.10M16.64-$177.71MN/AN/A

Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Ascentage Pharma Group International has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Ascentage Pharma Group International's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-317.62% -46.54% -36.46%
Ascentage Pharma Group International N/A N/A N/A

Arcturus Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 60.12%. Ascentage Pharma Group International has a consensus target price of $44.75, suggesting a potential upside of 205.88%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
3.18

Summary

Ascentage Pharma Group International beats Arcturus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Arcturus Therapeutics compare to Inhibrx Biosciences?

Arcturus Therapeutics (NASDAQ:ARCT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Inhibrx Biosciences has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Inhibrx Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics-317.62% -46.54% -36.46%
Inhibrx Biosciences N/A -563.90%-83.48%

In the previous week, Arcturus Therapeutics had 7 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for Arcturus Therapeutics and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.34 beat Arcturus Therapeutics' score of 0.15 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arcturus Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 60.12%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 107.87%. Given Inhibrx Biosciences' higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.67
Inhibrx Biosciences
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.50

Arcturus Therapeutics has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, indicating that its stock price is 281% more volatile than the broader market.

Arcturus Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$82.03M4.76-$65.78M-$3.31N/A
Inhibrx Biosciences$1.30M1,075.81-$140.05M-$8.88N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Arcturus Therapeutics beats Inhibrx Biosciences on 10 of the 16 factors compared between the two stocks.

Get Arcturus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARCT vs. The Competition

Export
MetricArcturus TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$365.80M$3.84B$7.16B$13.21B
Dividend YieldN/A3.66%2.53%20.71%
P/E Ratio-4.1513.42274.1326.16
Price / Sales4.761,237.44589.9795.24
Price / CashN/A116.5676.3853.09
Price / Book1.8217.1711.216.34
Net Income-$65.78M-$22.69M$3.50B$381.90M
7 Day Performance5.45%-1.20%-0.84%-1.39%
1 Month Performance-6.78%-9.68%-5.42%-4.31%
1 Year Performance-30.18%10.09%4.38%-0.35%

Arcturus Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARCT
Arcturus Therapeutics
2.8538 of 5 stars		$13.74
+6.8%		$22.00
+60.1%		-39.3%$365.80M$82.03MN/A111
MAZE
Maze Therapeutics
2.9034 of 5 stars		$26.43
flat		$63.40
+139.9%		-9.5%$1.47B$167.50MN/A141
COAG
Hemab Therapeutics
2.7082 of 5 stars		$30.59
-1.7%		$51.40
+68.0%		N/A$1.45BN/AN/A59
ANAB
AnaptysBio
3.2923 of 5 stars		$49.20
+1.4%		$77.79
+58.1%		+45.2%$1.45B$232.39M9.16104
AAPG
Ascentage Pharma Group International
3.8259 of 5 stars		$14.60
-4.9%		$46.43
+218.0%		-63.8%$1.44B$82.10MN/A767

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARCT) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel